CRSP data by YCharts Rising Treasury bond yields, inflation concerns, and geopolitical tensions weighed on growth stocks last month. What happened Shares of CRISPR Therapeutics (NASDAQ: CRSP) fell 10.4% in September, according to data from S&P Global Market Intelligence. CRSP data by YCharts CRISPR Therapeutics is valued at roughly $7.8 billion and trades at roughly 9.7 times this year's expected sales and 22 times this year's expected earnings.